Half-year report · Q2
4543.TEDINET S100UOKT
Period2024-04-01 → 2024-09-30
Filed2024-11-11
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥508.7bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥921.9bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥443.9bn | 2023-04-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥87.7bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥66.5bn | 2023-04-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥85.1bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥140.8bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥66.4bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥63.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥106.4bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥50.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥63.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥50.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥1.75T | at 2024-09-30 | Cons. | Assets IFRS |
| Total assets | ¥1.83T | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.75T | at 2023-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥438.8bn | at 2024-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥504.3bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.31T | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.33T | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.26T | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.11T | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.31T | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.33T | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.26T | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥194.9bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥204.9bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥187.3bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥187.3bn | at 2023-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥100.9bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥146.3bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥53.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥38.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥81.5bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥36.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥65.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥62.1bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥30.0bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥42.57 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥71.5 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥33.63 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥42.56 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥71.47 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥33.62 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 75.0% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 72.5% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 72.1% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue external | 2024-04-01 → 2024-09-30 | ¥132m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥98.0bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥13.2bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥306.3bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥76.9bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥104.3bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥12.7bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥508.6bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥102.8bn |
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2023-09-30 | ¥119m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥1.0bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥84.1bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥10.6bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥265.7bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥57.6bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥94.0bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥8.3bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥443.8bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥76.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 637
| Item | Context | Value | Unit |
|---|---|---|---|
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2024-04-01 | |
| Current period end date | FilingDateInstant | 2024-09-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2025-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2023-04-01 | |
| Comparative period end date | FilingDateInstant | 2023-09-30 | |
| Previous fiscal year end date | FilingDateInstant | 2024-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所プライム市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数100株 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)日本マスタートラスト信託銀行株式会社（信託口） | |
| Address major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)東京都港区赤坂１丁目８番１号 赤坂インターシティＡＩＲ | |
| Name major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)株式会社日本カストディ銀行（信託口） | |
| Address major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)東京都中央区晴海１丁目８－１２ | |
| Name major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)第一生命保険株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)東京都千代田区有楽町１丁目１３－１ | |
| Name major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Text · Plus | |
| Address major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Original text (Japanese)明治安田生命保険相互会社 | |
| Address major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Original text (Japanese)東京都千代田区丸の内２丁目１－１ | |
| Name major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Original text (Japanese)公益財団法人テルモ生命科学振興財団 | |
| Address major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Original text (Japanese)神奈川県足柄上郡中井町井ノ口１５００ | |
| Name major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Text · Plus | |
| Address major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Text · Plus | |
| Address major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |